Navigation Links
O2h Continues to Support Senexis to Support Patent Filing Senexis Limited

CAMBRIDGE, England, June 14, 2010 /PRNewswire/ -- Executives from Senexis Limited (Cambridge,UK) signed an agreement with O2h (Ahmedabad, India) under which O2h will provide Senexis with chemistry services to support a patent filing on a novel chemical series that have shown potential in pre-clinical models, as disease modifying treatments for Alzheimer's Disease.

Dr. Mark Treherne, CEO of Senexis said that he appreciated O2h's continual support over the last 4 years in being a reliable chemistry partner, providing flexible multi-FTE chemistry support to the company.

Dr David Scopes, CSO at Senexis said "We have had a long collaboration with O2h and are happy that it is supporting us to further our programs into the important stage of patent applications. Senexis is again leveraging O2h's expertise on the synthetic chemistry methodology underpinning our lead compounds."

Sunil Shah, CEO, O2h "We have an incredibly good relationship and I was very happy learn about the positive Senexis data from their pre-clinical studies which allowed the Wellcome Trust to continue supporting this programme."

About Oxygen Healthcare Ltd

O2h is a 5 year old discovery services company co-located in Cambridge, UK and Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at

About Senexis Limited

Senexis is a drug discovery and development company, dedicated to the discovery of effective treatments and diagnostics for major ageing-related diseases, such as Alzheimer's dementia. It is now widely believed that the misfolding and aggregation of amyloid-like proteins underlies the pathologies of Alzheimer's disease and Senexis has discovered potent and selective compounds that protect cells and tissues from the toxic forms of amyloid. Senexis is now actively seeking development partners and further information on Senexis can be found at

    Contact information:
    Ekta Ahuja PhD
    23 Cambridge Science Park
    CB4 0EY

    Babraham Research Campus
    Babraham, Cambridge, UK
    CB22 3AT

SOURCE Oxygen Healthcare Ltd (O2h)
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
3. Dehaier Medical Systems Continues Product Line Expansion. Signs Exclusive Distribution Agreement with HEYER Medical for Respiratory Products in China
4. US Oncology Continues to Set the Standard as a VAWD(CM) Accredited Wholesale Distributor
5. Igen Networks Corp continues to build a world class advisory board
6. Indiana Continues to Make Its Mark as a Leading Life Sciences Center
7. Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor
8. The MedZilla Report for January 2010 - Health Care Closes 2009 Strong, But Pharma Continues Shedding Jobs
9. TechCFO Continues Research Triangle Park Expansion; Garrison Named New Partner
10. Arena Pharmaceuticals Announces Merck Discontinues Development of Investigational Niacin Receptor Agonist Program for Atherosclerosis
11. Health Robotics Continues its Global Expansion With December 09 ASHPs Launch of Joint Venture in Canada
Post Your Comments:
(Date:10/13/2015)... ... , ... Clinovo recently appointed Jeff Parr and Ed Donaldson to its Business ... business. , Jeff Parr has spent the past decade providing quality management software and ... and Ab Sciex to name a few. He is based in Salt Lake ...
(Date:10/13/2015)... -- the United States , ... about 14% of all new cases of kidney cancer.   ... and Europe .  PRCC represents about ... Hutchison China MediTech Limited ("Chi-Med") (AIM: HCM) today announces that ... (publ) ("AstraZeneca") have completed enrolment in a global Phase II study ...
(Date:10/12/2015)... NEW YORK , Oct. 12, 2015 ... its segments, which include cell type, products, applications, end-user ... REPORT HIGHLIGHTS The global cell expansion ... and is expected to reach revenues of $9.7 billion ... compound annual growth rate (CAGR) of 17.8% from 2015 ...
(Date:10/12/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... developing and commercializing novel treatments in oncology, endocrinology and ... Turpin , the Company,s former Senior Vice President, Chief ... Quebec City office.  ... Officer of the Company commented, "After a comprehensive review, ...
Breaking Biology Technology:
(Date:9/30/2015)... 2015  With nearly 300,000 Americans living with spinal ... estimated to reach 12,500 annually, the role of Independent ... for Independent Living (SCRS-IL) is increasingly important. SCRS-IL ... opening doors to independence for individuals with ... notably assistive technology services and education. "In ...
(Date:9/29/2015)... 2015 News facts: ... saving energy , Minimized design shrinks PC footprint ... Mode and embedded Fujitsu PalmSecure authentication enable enterprises to ... today shows that good things come in small packages, ... its enterprise desktop and mobile portfolio. Featuring workplace design ...
(Date:9/28/2015)... NEW YORK , Sept. 28, 2015 /PRNewswire/ ... rate, respiration rate and body temperature, is an ... signs can be indicators of deterioration in a ... the hospital, vital signs are typically taken during ... eight hours. If a patient deteriorates between these ...
Breaking Biology News(10 mins):